MA47079A - Composés amino-triazolopyidines et leur utilisation pour traiter le cancer - Google Patents
Composés amino-triazolopyidines et leur utilisation pour traiter le cancerInfo
- Publication number
- MA47079A MA47079A MA047079A MA47079A MA47079A MA 47079 A MA47079 A MA 47079A MA 047079 A MA047079 A MA 047079A MA 47079 A MA47079 A MA 47079A MA 47079 A MA47079 A MA 47079A
- Authority
- MA
- Morocco
- Prior art keywords
- compounds
- salts
- triazolopyidine
- amino
- treat cancer
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Abstract
L'invention concerne d'une manière générale des composés de formule (i) et des sels pharmaceutiquement acceptables de ceux-ci. Dans la formule (i), r1 et r2 peuvent prendre une quelconque des significations définies dans la description. L'invention concerne également l'utilisation de ces composés et de leurs sels pour traiter ou prévenir une maladie induite par dna-pk, y compris le cancer. L'invention concerne en outre, des compositions pharmaceutiques et des kits comprenant lesdits composés et sels ; des procédés de fabrication desdits composés et sels ; des intermédiaires utiles dans la fabrication desdits composés et sels ; et des procédés de traitement de maladies induites par dna-pk, y compris le cancer, par l'utilisation desdits composés et sels.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662436619P | 2016-12-20 | 2016-12-20 | |
PCT/EP2017/083625 WO2018114999A1 (fr) | 2016-12-20 | 2017-12-19 | Composés amino-triazolopyridine et leur utilisation dans le traitement du cancer |
Publications (2)
Publication Number | Publication Date |
---|---|
MA47079A true MA47079A (fr) | 2019-10-30 |
MA47079B1 MA47079B1 (fr) | 2021-05-31 |
Family
ID=60937727
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA47079A MA47079B1 (fr) | 2016-12-20 | 2017-12-19 | Composés amino-triazolopyidines et leur utilisation pour traiter le cancer |
Country Status (38)
Country | Link |
---|---|
US (4) | US10407446B2 (fr) |
EP (1) | EP3558997B1 (fr) |
JP (1) | JP6883653B2 (fr) |
KR (1) | KR102220971B1 (fr) |
CN (1) | CN110177791B (fr) |
AR (1) | AR110400A1 (fr) |
AU (1) | AU2017384388B2 (fr) |
BR (1) | BR112019012217B1 (fr) |
CA (1) | CA3046339C (fr) |
CL (1) | CL2019001714A1 (fr) |
CO (1) | CO2019007810A2 (fr) |
CR (1) | CR20190301A (fr) |
CY (1) | CY1124239T1 (fr) |
DK (1) | DK3558997T3 (fr) |
DO (1) | DOP2019000168A (fr) |
EA (1) | EA037745B1 (fr) |
EC (1) | ECSP19044159A (fr) |
ES (1) | ES2867274T3 (fr) |
HR (1) | HRP20210548T1 (fr) |
HU (1) | HUE054548T2 (fr) |
IL (1) | IL267158B (fr) |
JO (1) | JOP20190151B1 (fr) |
LT (1) | LT3558997T (fr) |
MA (1) | MA47079B1 (fr) |
MX (1) | MX2019007189A (fr) |
MY (1) | MY183036A (fr) |
NI (1) | NI201900062A (fr) |
NZ (1) | NZ755222A (fr) |
PE (1) | PE20191474A1 (fr) |
PH (1) | PH12019501350A1 (fr) |
PL (1) | PL3558997T3 (fr) |
PT (1) | PT3558997T (fr) |
RS (1) | RS61701B1 (fr) |
SI (1) | SI3558997T1 (fr) |
TW (1) | TWI776835B (fr) |
UA (1) | UA123032C2 (fr) |
WO (1) | WO2018114999A1 (fr) |
ZA (1) | ZA201904695B (fr) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JOP20190151B1 (ar) | 2016-12-20 | 2023-09-17 | Astrazeneca Ab | مركبات أمينو - ترايازولو بيريدين واستخدامها في علاج سرطان |
TWI820146B (zh) * | 2018-06-15 | 2023-11-01 | 瑞典商阿斯特捷利康公司 | 嘌呤酮化合物及其在治療癌症中之用途 |
WO2020186211A1 (fr) * | 2019-03-13 | 2020-09-17 | The Uab Research Foundation | Procédés et compositions pour le traitement d'une infection par le polyomavirus |
TW202110849A (zh) * | 2019-05-27 | 2021-03-16 | 大陸商迪哲(江蘇)醫藥股份有限公司 | Dna依賴性蛋白激酶抑制劑 |
WO2020254872A2 (fr) | 2019-06-17 | 2020-12-24 | Crispr Therapeutics Ag | Méthodes et compositions pour la réparation dirigée par l'homologie améliorée |
IL293211A (en) * | 2019-11-22 | 2022-07-01 | Medshine Discovery Inc | Pyrimidopyrrole spiro compounds and their derivatives as dna-pk inhibitors |
TWI807228B (zh) * | 2019-11-25 | 2023-07-01 | 大陸商南京明德新藥研發有限公司 | 作為dna-pk抑制劑的嘧啶并吡咯類化合物 |
CR20220282A (es) * | 2019-11-26 | 2022-11-28 | Primmune Therapeutics Inc | Agonistas del tlr7 |
WO2021136463A1 (fr) * | 2019-12-31 | 2021-07-08 | 成都百裕制药股份有限公司 | Dérivé purine et son utilisation médicale |
CN113121573A (zh) * | 2019-12-31 | 2021-07-16 | 成都百裕制药股份有限公司 | 嘌呤衍生物及其在医药上的应用 |
WO2021136462A1 (fr) * | 2019-12-31 | 2021-07-08 | 成都百裕制药股份有限公司 | Dérivés furane et leur application en médecine |
CN113493471A (zh) * | 2020-04-03 | 2021-10-12 | 山东轩竹医药科技有限公司 | 杂芳环类激酶抑制剂 |
CN113549092B (zh) * | 2020-04-23 | 2022-10-18 | 山东轩竹医药科技有限公司 | 三并环类激酶抑制剂 |
JP2023524666A (ja) | 2020-04-28 | 2023-06-13 | インテリア セラピューティクス,インコーポレイテッド | インビトロ細胞送達の方法 |
WO2021260583A1 (fr) | 2020-06-24 | 2021-12-30 | Astrazeneca Uk Limited | Association d'un conjugué anticorps-médicament et d'un inhibiteur de la dna-pk |
WO2022017368A1 (fr) * | 2020-07-20 | 2022-01-27 | 首药控股(北京)股份有限公司 | Inhibiteur sélectif de dna-pk, son procédé de préparation et son utilisation |
US20220040173A1 (en) * | 2020-08-04 | 2022-02-10 | Astrazeneca Ab | Methods of delaying pain progression and treating prostate cancer |
CN114249753A (zh) * | 2020-09-22 | 2022-03-29 | 山东轩竹医药科技有限公司 | 三唑并吡啶类激酶抑制剂 |
CN114634522A (zh) * | 2020-12-15 | 2022-06-17 | 江苏恒瑞医药股份有限公司 | 嘌呤酮衍生物、其制备方法及其在医药上的应用 |
AU2021400745A1 (en) | 2020-12-17 | 2023-07-20 | Vertex Pharmaceuticals Incorporated | Compositions and methods for editing beta-globin for treatment of hemaglobinopathies |
TW202241901A (zh) * | 2020-12-21 | 2022-11-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 嘌呤酮衍生物、其製備方法及其在醫藥上的應用 |
CN114656487B (zh) * | 2020-12-22 | 2023-11-14 | 江苏恒瑞医药股份有限公司 | 稠合嘧啶类化合物、其制备方法及其在医药上的应用 |
TW202229281A (zh) * | 2020-12-24 | 2022-08-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 嘌呤酮類化合物、其製備方法及其在醫藥上的應用 |
WO2022199547A1 (fr) * | 2021-03-22 | 2022-09-29 | 成都赜灵生物医药科技有限公司 | Dérivé de 7,9-dihydropurine et son usage pharmaceutique |
AU2022258733A1 (en) | 2021-04-17 | 2023-11-30 | Intellia Therapeutics, Inc. | Inhibitors of dna-dependent protein kinase and compositions and uses thereof |
TWI812223B (zh) * | 2021-05-19 | 2023-08-11 | 大陸商再鼎醫藥(上海)有限公司 | 雜環取代的嘌呤酮衍生物的鹽型及晶型 |
CN117377676A (zh) * | 2021-06-29 | 2024-01-09 | 成都百裕制药股份有限公司 | 嘌呤衍生物的晶型及其药物组合物 |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
TR199801530T2 (xx) | 1996-02-13 | 1998-11-23 | Zeneca Limited | VEGF �nhibit�rleri olarak kinazolin t�revleri. |
JP4464466B2 (ja) | 1996-03-05 | 2010-05-19 | アストラゼネカ・ユーケイ・リミテッド | 4―アニリノキナゾリン誘導体 |
GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
US6432947B1 (en) | 1997-02-19 | 2002-08-13 | Berlex Laboratories, Inc. | N-heterocyclic derivatives as NOS inhibitors |
JP4895811B2 (ja) | 2003-09-11 | 2012-03-14 | ケミア,インコーポレイテッド | サイトカイン阻害剤 |
US20070191447A1 (en) | 2004-02-23 | 2007-08-16 | Toru Kodo | Novel heterocyclic compound |
AU2006205851A1 (en) | 2005-01-14 | 2006-07-20 | Janssen Pharmaceutica N.V. | 5-membered annelated heterocyclic pyrimidines as kinase inhibitors |
GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
WO2007035873A1 (fr) | 2005-09-21 | 2007-03-29 | Pharmacopeia, Inc. | Dérivés de purinone pour le traitement de maladies neurodégénératives |
EA200800664A1 (ru) | 2005-10-13 | 2009-02-27 | Глаксо Груп Лимитед | Производные пирролопиримидина в качестве ингибиторов syk |
WO2007058990A2 (fr) | 2005-11-14 | 2007-05-24 | Kemia, Inc. | Therapie a base d’inhibiteurs de cytokine |
TWI398252B (zh) | 2006-05-26 | 2013-06-11 | Novartis Ag | 吡咯并嘧啶化合物及其用途 |
AU2007257959A1 (en) | 2006-06-09 | 2007-12-21 | Kemia, Inc. | Therapy using cytokine inhibitors |
US7902187B2 (en) * | 2006-10-04 | 2011-03-08 | Wyeth Llc | 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression |
AR063142A1 (es) * | 2006-10-04 | 2008-12-30 | Pharmacopeia Inc | Derivados de 2-(bencimidazolil) purina y purinonas 6-sustituidas utiles como inmunosupresores,y composiciones farmaceuticas que los contienen. |
NZ576278A (en) | 2006-10-19 | 2011-12-22 | Signal Pharm Llc | Heteroaryl compounds, compositions thereof, and their use as protein kinase inhibitors |
ES2608940T3 (es) | 2007-06-15 | 2017-04-17 | Msd K.K. | Derivado de bicicloanilina |
KR20100057650A (ko) | 2007-08-23 | 2010-05-31 | 아스트라제네카 아베 | 증식성 질환의 치료를 위한 ttk/mps1의 억제제로서 2-아닐리노푸린-8-온 |
US20100056524A1 (en) * | 2008-04-02 | 2010-03-04 | Mciver Edward Giles | Compound |
JP2012197231A (ja) | 2009-08-06 | 2012-10-18 | Oncotherapy Science Ltd | Ttk阻害作用を有するピリジンおよびピリミジン誘導体 |
AR079814A1 (es) | 2009-12-31 | 2012-02-22 | Otsuka Pharma Co Ltd | Compuestos heterociclicos, composiciones farmaceuticas que los contienen y sus usos |
BR112012019459A2 (pt) | 2010-02-03 | 2017-10-17 | Signal Pharm Llc | identificação de mutação de lkb1 como um biomarcador preditivo para sensibilidade para inibidores de tor quinase. |
JP5918214B2 (ja) | 2010-04-13 | 2016-05-18 | ノバルティス アーゲー | がんを治療するためのサイクリン依存性キナーゼ4またはサイクリン依存性キナーゼ(cdk4/6)阻害剤およびmtor阻害剤を含む組合せ |
WO2012143143A1 (fr) | 2011-04-21 | 2012-10-26 | Origenis Gmbh | Composés hétérocycliques en tant qu'inhibiteurs de kinases |
UY34032A (es) | 2011-04-21 | 2012-11-30 | Origenis Gmbh | Nuevos inhibidores de quinasa |
EP2527344A1 (fr) * | 2011-05-25 | 2012-11-28 | Almirall, S.A. | Dérivés de pyridin-2(1h)-one utiles comme médicaments pour le traitement de maladies myeloproliferatives, de rejets de greffe, de maladies a médiation immune et de maladies inflammatoires |
JP6121658B2 (ja) | 2011-06-29 | 2017-04-26 | 大塚製薬株式会社 | 治療用化合物、及び関連する使用の方法 |
TWI708605B (zh) | 2011-10-19 | 2020-11-01 | 標誌製藥公司 | 以tor激酶抑制劑治療癌症 |
BR112014022697A2 (pt) * | 2012-03-15 | 2020-06-30 | Signal Pharmaceuticals, Llc | Uso de uma quantidade eficaz de um inibidor de quinase tor,método para melhorar o critério de avaliação de resposta,método para a inibição da fosforilação, método para a inibiçãoda atividade da proteína, método para a medição da inibição dafosforilação, kit |
CN102675897B (zh) | 2012-05-18 | 2015-04-29 | 陕西师范大学 | 硫脲/脲芳胺染料及其制备方法和应用 |
CN103864792B (zh) | 2012-12-12 | 2017-01-18 | 山东亨利医药科技有限责任公司 | 作为酪氨酸激酶抑制剂的含氮并环类化合物 |
WO2014134240A1 (fr) | 2013-02-28 | 2014-09-04 | Signal Pharmaceuticals, Llc | Traitement du cancer avec des inhibiteurs de la kinase tor |
NO2714752T3 (fr) | 2014-05-08 | 2018-04-21 | ||
JOP20190151B1 (ar) | 2016-12-20 | 2023-09-17 | Astrazeneca Ab | مركبات أمينو - ترايازولو بيريدين واستخدامها في علاج سرطان |
-
2017
- 2017-12-19 JO JOP/2019/0151A patent/JOP20190151B1/ar active
- 2017-12-19 PT PT178258299T patent/PT3558997T/pt unknown
- 2017-12-19 SI SI201730707T patent/SI3558997T1/sl unknown
- 2017-12-19 KR KR1020197021026A patent/KR102220971B1/ko active IP Right Grant
- 2017-12-19 MY MYPI2019003492A patent/MY183036A/en unknown
- 2017-12-19 LT LTEP17825829.9T patent/LT3558997T/lt unknown
- 2017-12-19 MA MA47079A patent/MA47079B1/fr unknown
- 2017-12-19 CR CR20190301A patent/CR20190301A/es unknown
- 2017-12-19 JP JP2019533052A patent/JP6883653B2/ja active Active
- 2017-12-19 PE PE2019001276A patent/PE20191474A1/es unknown
- 2017-12-19 ES ES17825829T patent/ES2867274T3/es active Active
- 2017-12-19 DK DK17825829.9T patent/DK3558997T3/da active
- 2017-12-19 AR ARP170103582A patent/AR110400A1/es unknown
- 2017-12-19 CA CA3046339A patent/CA3046339C/fr active Active
- 2017-12-19 MX MX2019007189A patent/MX2019007189A/es unknown
- 2017-12-19 UA UAA201907754A patent/UA123032C2/uk unknown
- 2017-12-19 HU HUE17825829A patent/HUE054548T2/hu unknown
- 2017-12-19 RS RS20210447A patent/RS61701B1/sr unknown
- 2017-12-19 EA EA201991399A patent/EA037745B1/ru unknown
- 2017-12-19 NZ NZ755222A patent/NZ755222A/en unknown
- 2017-12-19 WO PCT/EP2017/083625 patent/WO2018114999A1/fr unknown
- 2017-12-19 AU AU2017384388A patent/AU2017384388B2/en active Active
- 2017-12-19 BR BR112019012217-6A patent/BR112019012217B1/pt active IP Right Grant
- 2017-12-19 US US15/846,679 patent/US10407446B2/en active Active
- 2017-12-19 EP EP17825829.9A patent/EP3558997B1/fr active Active
- 2017-12-19 CN CN201780078065.XA patent/CN110177791B/zh active Active
- 2017-12-19 PL PL17825829T patent/PL3558997T3/pl unknown
- 2017-12-20 TW TW106144799A patent/TWI776835B/zh active
-
2019
- 2019-06-06 IL IL267158A patent/IL267158B/en active IP Right Grant
- 2019-06-14 PH PH12019501350A patent/PH12019501350A1/en unknown
- 2019-06-17 DO DO2019000168A patent/DOP2019000168A/es unknown
- 2019-06-19 CL CL2019001714A patent/CL2019001714A1/es unknown
- 2019-06-20 EC ECSENADI201944159A patent/ECSP19044159A/es unknown
- 2019-06-20 NI NI201900062A patent/NI201900062A/es unknown
- 2019-07-17 ZA ZA2019/04695A patent/ZA201904695B/en unknown
- 2019-07-19 CO CONC2019/0007810A patent/CO2019007810A2/es unknown
- 2019-07-30 US US16/526,219 patent/US11136340B2/en active Active
-
2021
- 2021-04-07 HR HRP20210548TT patent/HRP20210548T1/hr unknown
- 2021-04-27 CY CY20211100360T patent/CY1124239T1/el unknown
- 2021-08-27 US US17/459,049 patent/US11746118B2/en active Active
-
2023
- 2023-07-10 US US18/349,220 patent/US20240124492A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA47079A (fr) | Composés amino-triazolopyidines et leur utilisation pour traiter le cancer | |
MA44674A (fr) | Inhibiteurs de bromodomaine | |
MA42295B1 (fr) | Composés de la benzoxazépin oxazolidinone et procédé pour leur utilisation | |
MA38391A1 (fr) | Dérivés de pyridinyl et triazolone pyridinyl de fusion | |
MA41134B1 (fr) | Composés substitués de 5-amino-6h-thiazolo[4,5-d]pyrimidine-2,7-dione pour le traitement et la prophylaxie des infections virales | |
EA202190006A1 (ru) | Пуриноновые соединения и их применение при лечении рака | |
MA37762A1 (fr) | Composés n-aryltriazole utilisés comme antagonistes de lpar | |
MA35285B1 (fr) | Indazoles | |
MA34898B1 (fr) | Nouveaux dérivés hétérocycliques et leur utilisation dans le traitement de troubles neurologiques | |
MA38099B1 (fr) | Des nouveaux composes triazolopyrazines substitues inhibiteurs des brd4 | |
MA32070B1 (fr) | Dérivés hétérocycliques réunis par fusion et procédés d'utilisation associés | |
PH12018500957A1 (en) | Imidazo[4,5-c] quinolin -2-one compounds and their use in treating cancer | |
EA200701808A1 (ru) | Производные тетрагидроиндолона и тетрагидроиндазолона | |
MA51524A (fr) | Composés, compositions et méthodes pour le traitement de maladies impliquant des tissus malades acides ou hypoxiques | |
TN2016000188A1 (fr) | Derives de purines 2,6-substitues et leur utilisation dans le traitement de troubles proliferatifs. | |
MA33419B1 (fr) | Composés et compositions pour le traitement de maladies parasitaires | |
MA38240B1 (fr) | Nouveaux composes dimeres substitues antagonistes de l'iap utiles pour le traitement du cancer, de preference des tumeurs solides | |
ATE540038T1 (de) | Heterocyclen als proteinkinaseinhibitoren | |
MA39926B1 (fr) | Dérivés de dihétérocycle liés à cycloalkyle | |
MA39524A1 (fr) | 1h-1,8-naphthyridin-2 ones utilisées comme composés anti prolifératifs | |
MA39229A1 (fr) | Pyrrolidines, térahydrofuranes et cyclopentanes substitués utiles en tant qu'antagonistes des récepteurs des orexines | |
MA53372B1 (fr) | Pyridopyrimidinones comme inhibiteurs du récepteur h4 de l'histamine | |
MA37748A1 (fr) | Composés d'azétidine et de pipéridine utiles comme inhibiteurs de pde10 | |
MA37291A2 (fr) | Dérivés macrocycliques pour le traitement de maladies prolifératives | |
MA52370B1 (fr) | Dérivés de la pyridine et leurs utilisations thérapeutiques comme inhibiteurs du trpc6 |